Standard BioTools Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Standard BioTools Inc. (LAB) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 75.16 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2025-03-11
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-03-31 was 75.16M shares, a 13.58% increase year-over-year.
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2022-03-31 was 66.18M shares.
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2023 was 75.16M shares, a 0.00% change from fiscal 2022.
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2022 was 75.16M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|---|---|
| 2023-12-31 | 75.16M shares 10-K · filed 2025-03-11 | |||
| 2023-09-30 | 75.16M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 75.16M shares 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 75.16M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 75.16M shares 10-K · filed 2025-03-11 | |||
| 2022-09-30 | 75.16M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 75.16M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 66.18M shares 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |